Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 2
1999 3
2000 1
2001 2
2002 4
2003 7
2004 5
2005 8
2006 10
2007 4
2008 6
2009 15
2010 9
2011 13
2012 20
2013 23
2014 32
2015 19
2016 27
2017 25
2018 48
2019 75
2020 101
2021 123
2022 83
2023 36
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29275833

630 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.
Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM. Zhang Q, et al. Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21. Eur Urol. 2018. PMID: 29275833 Free PMC article. Review.
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P, Thomas O, Nolan-Stevaux O, Li S, Wahl J, Bogner P, Aeffner F, Friedrich M, Liao MZ, Matthes K, Rau D, Rattel B, Raum T, Kufer P, Coxon A, Bailis JM. Deegen P, et al. Clin Cancer Res. 2021 May 15;27(10):2928-2937. doi: 10.1158/1078-0432.CCR-20-3725. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504551
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, Davison L, Harris KE, Pham D, Sankaran P, Ugamraj HS, Deng R, Kwek S, Starzinski A, Iyer S, van Schooten W, Schellenberger U, Sun W, Trinklein ND, Buelow R, Buelow B, Fong L, Dalvi P. Dang K, et al. J Immunother Cancer. 2021 Jun;9(6):e002488. doi: 10.1136/jitc-2021-002488. J Immunother Cancer. 2021. PMID: 34088740 Free PMC article.
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Hernandez-Hoyos G, Sewell T, Bader R, Bannink J, Chenault RA, Daugherty M, Dasovich M, Fang H, Gottschalk R, Kumer J, Miller RE, Ravikumar P, Wiens J, Algate PA, Bienvenue D, McMahan CJ, Natarajan SK, Gross JA, Blankenship JW. Hernandez-Hoyos G, et al. Mol Cancer Ther. 2016 Sep;15(9):2155-65. doi: 10.1158/1535-7163.MCT-15-0242. Epub 2016 Jul 12. Mol Cancer Ther. 2016. PMID: 27406985
630 results